Académique Documents
Professionnel Documents
Culture Documents
disease
Pinpointing clinical manifestations and best management
Gregorio T. Obrador, MD, MPH; Brian J. G. Pereira, MD, MBA
VOL 111 / NO 2 / FEBRUARY 2002 / POSTGRADUATE MEDICINE
Pathophysiology of uremia
Although the pathogenesis of the different uremic symptoms is not completely
understood, three major mechanisms are involved: diminished excretion of electrolytes
and water, reduced excretion of organic solutes, and decreased hormone production (1,2).
Diminished excretion of electrolytes and water
An important function of the healthy kidney is to excrete the electrolytes and water
generated from dietary intake in order to maintain a steady state in which intake and
urinary excretion are roughly equal. The conditions that cause loss of kidney function
induce adaptive mechanisms that attempt to preserve the homeostatic state of electrolyte
and water balance. If, for example, three quarters of nephrons have been lost, then each
remaining nephron must excrete four times the amount of electrolytes and water to
maintain the excretion at the same level of dietary intake.
However, all these compensatory mechanisms eventually fail, at which stage the
continual loss of function results in the kidney's inability to maintain balance. At this
point, patients are said to have end-stage renal disease (ESRD). The number of
functioning nephrons at this time is so small that urinary excretion cannot achieve a level
equal to intake. Clinical manifestations include edema and hypertension (caused by
sodium retention), hyponatremia (resulting from free water retention), hyperkalemia,
metabolic acidosis, hyperuricemia, and hyperphosphatemia.
Reduced excretion of organic solutes
The kidneys excrete a variety of organic solutes, the most commonly measured ones
being urea and creatinine. Unlike the excretion of electrolytes and water, the excretion of
urea and creatinine is not actively regulated. Thus the plasma level of these solutes begins
to rise with the initial decline in GFR and increases progressively as kidney function
deteriorates. Once the GFR falls below 15 mL/min/1.73m , patients begin to complain of
many of the manifestations listed in table 1. It is thought that many of these symptoms
are mediated by an accumulation of uremic toxins. However, it is not yet possible to
identify the toxins responsible for most uremic symptoms (3). Although it has been
postulated that urea may be an important toxin, symptoms of uremia correlate only
inconsistently with the level of urea.
2
Neurologic
Endocrine
Skin
Pruritus
If sodium restriction is not effective or not achieved, diuretics should be used (5).
Thiazide diuretics are usually ineffective if the serum creatinine level is greater than 3
mg/dL (>265 micromole/L). Thus, more potent loop diuretics are the agents of choice in
patients with CKD. The initial aim is to determine the threshold dose that is effective.
Patients with advanced CKD may require doses of furosemide (Lasix) as high as 400 mg
per day. Lack of response to high doses of loop diuretics often is due to noncompliance
with dietary sodium restriction. In such cases, a combination of a thiazide diuretic or
metolazone (Mykrox, Zaroxolyn) given before the loop diuretic may induce diuresis. For
maximum efficacy, the thiazide diuretic should be given 30 minutes before the loop
diuretic. Potassium-sparing diuretics (eg, spironolactone [Aldactone]) are contraindicated
because of the risk of inducing hyperkalemia.
Potassium balance: Potassium balance and plasma potassium level are also maintained
until very late in CKD, mainly because of an increase in renal excretion of potassium per
functioning nephron and an increase in potassium output in the stool (6). Hyperkalemia
may develop earlier in the course of CKD in patients with hyporeninemic
hypoaldosteronism, a complication usually seen in patients with diabetic nephropathy or
tubulointerstitial disease.
Hyperkalemia may occur in association with dietary indiscretion (eg, excessive
consumption of chocolate, dried fruits, or bananas), use of potassium-containing salt
substitutes, increased catabolism (as with severe intercurrent illness), or metabolic
acidosis. It may also be seen with the use of potassium-sparing diuretics, angiotensinconverting enzyme (ACE) inhibitors, and nonsteroidal anti-inflammatory drugs
(NSAIDs). Hypokalemia may occasionally occur in patients with CKD, and it is usually
due to gastrointestinal losses or excessive use of the cation exchange resin sodium
polystyrene sulfonate (Kayexalate, SPS).
Mild hyperkalemia in the range of 5 to 5.5 mEq/L is a common feature in patients with
CKD and requires dietary potassium restriction to 2 to 3 g (50 to 75 mEq) per day as well
as discontinuation of any offending drug. Patients with a serum potassium concentration
12
Although white blood cell count is usually within normal range when CKD is present, the
function of these cells may be defective, leading to an increased susceptibility to
infections (20). Other common effects include an increased capillary fragility and
bleeding tendency resulting from defective platelet function.
Bone disease
Metabolism of calcium and phosphorus is abnormal in patients with CKD and is
associated with the development of bone disease. Phosphate retention occurs as GFR
declines. Both hyperphosphatemia and, more important, reduction in the active form of
vitamin D (1,25-dihydroxycholecalciferol) lead to hypocalcemia. (The active form of
vitamin D is normally produced by the kidney and increases calcium absorption in the
intestine.) As attempts are made to normalize the serum calcium level, secondary
hyperparathyroidism can develop, causing significant bone damage (figure 1) to occur
(21,22).
The spectrum of bone disease, also known as renal osteodystrophy, includes osteitis
fibrosa, osteomalacia, and adynamic bone disease. The most common form is osteitis
fibrosa caused by secondary hyperparathyroidism. Although initially asymptomatic,
osteitis fibrosa can produce bone pain, pathologic fractures, and metastatic calcifications
in its more advanced stages. The complications associated with hyperparathyroidism can
be prevented or minimized by controlling hyperphosphatemia and by lowering the
parathyroid hormone level (table 3) (23).
Table 3. Treatment of abnormal calcium and phosphorus balance in chronic kidney
disease
General goals
Treatment is directed first at control of hyperphosphatemia and thereafter at control of
PTH secretion.
Hyperphosphatemia
The goal is to maintain serum phosphate levels in the upper range of normal (4.5-5.5
mg/dL [1.5-1.8 mmol/L]).
A low-phosphorus diet (<800 g/day) should be attempted first but is difficult to attain.
Phosphate binders are used as follows:
Aluminum hydroxide and magnesium-containing antacids should not be used because of
the risk of aluminum toxicity and hypermagnesemia.
Calcium carbonate and calcium acetate are the binders of choice because they are
effective phosphate binders and also correct hypocalcemia.
Start with 1 to 2 tablets three times per day with meals and increase dose until
serum phosphorus level falls to <5.5 mg/dL (<1.8 mmol/L).
Daily dose ranges from 2 to 10 g of binder.
Monitor serum calcium level because of the risk of hypercalcemia.
Sevelamer HCl (Renagel) can also be considered because it is a cationic polymer that
binds phosphate through ion exchange. It is as effective as calcium acetate and does not
cause hypercalcemia, but it is considerably more expensive.
PTH suppression
The goal is to achieve a PTH level 2 to 3 times normal (130-195 pg/mL [13.7-20.5
pmol/L]).
Calcitriol (1,25-dihydroxycholecalciferol) (Calcijex, Rocaltrol) is used as follows:
Treatment should be started in patients with a PTH level of >200 pg/mL (>21
pmol/L) only after the phosphate level has been controlled (<6.5 mg/dL [2.1
mmol/L]).
Low-dose therapy (0.25 mg/day) may be as effective as pulse therapy (2 to 3 times
per week).
Complications of therapy include adynamic bone disease resulting from excessive
PTH suppression and hypercalcemia.
Neurologic complications
Cerebrovascular accidents of all types are common in CKD. Uremic encephalopathy is
often seen in advanced kidney failure and is characterized by insomnia, impairment of
concentration, alterations in usual sleep rhythms, lability of emotion, anxiety, and
depression. Dialysis produces rapid clearing of the mental state and correction of
abnormal electroencephalographic findings. Generalized motor seizures may also occur
in patients with advanced kidney failure.
A symmetrical polyneuropathy of a mixed sensory-motor type is commonly seen.
Sensory symptoms present first (eg, cramps, paresthesias, restless legs). Disturbances in
autonomic function may cause postural hypotension and impotence (24).
References
1. Rose BD, Rennke HG. Signs and symptoms of chronic renal failure. Renal
pathophysiology--the essentials. Baltimore: Williams & Wilkins, 1994;276-300
2. Bailey JL, Mitch WE. Pathophysiology of uremia. In: Brenner BM, ed. Brenner
& Rector's the kidney. Vol 2. 6th ed. Philadelphia: WB Saunders, 2000;2059-78
3. Ringoir S. An update on uremic toxins. Kidney Int 1997;52(Suppl 62):S2-4
4. The Sixth Report of the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure. Bethesda: National Institutes
of Health, National Heart, Lung, and Blood Institute, 1997
5. Suki WN. Use of diuretics in chronic renal failure. Kidney Int 1997;51(Suppl
59):S33-5
6. Allon M. Hyperkalemia in end-stage renal disease: mechanisms and management.
J Am Soc Nephrol 1995;6(4):1134-42
7. Warnock DG. Uremic acidosis. Kidney Int 1998;34(2):278-87
8. Santella RN. Chronic renal insufficiency. In: Gennari FJ, ed. Medical
management of kidney and electrolyte disorders. New York: Marcel Dekker,
2001;269-92
9. Alpern RJ, Sakhaee K. The clinical spectrum of chronic metabolic acidosis:
homeostatic mechanisms produce significant morbidity. Am J Kidney Dis
1997;29(2):291-302
10. Etemad B. Gastrointestinal complications of renal failure. Gastroenterol Clin
North Am 1998;27(4):875-92
11. Ikizler TA, Hakim RM. Nutrition in end-stage renal disease. Kidney Int
1996;50(2):343-57
12. Buckalew VM Jr, Berg RL, Wang S-R, et al. Prevalence of hypertension in
1,795 subjects with chronic renal disease: the modification of diet in renal disease
study baseline cohort. Modification of Diet in Renal Disease Study Group. Am J
Kidney Dis 1996;28(6):811-21
13. Preston RA, Singer I, Epstein M. Renal parenchymal hypertension: current
concepts of pathogenesis and management. Arch Intern Med 1996;156(6):602-11
14. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-convertingenzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N
Engl J Med 1993;329(20):1456-62
15. Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors
on the progression of nondiabetic renal disease: a meta-analysis of randomized
trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease
Study Group. Ann Intern Med 1997;127(5):337-45
16. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated
elevations in serum creatinine: Is this a cause for concern? Arch Intern Med
2000;160(5):685-93
17. Rutsky EA, Rostand SG. Treatment of uremic pericarditis and pericardial
effusion. Am J Kidney Dis 1987;10(1):2-8
18. Erslev AJ, Besarab A. Erythropoietin in the pathogenesis and treatment of the
anemia of chronic renal failure. Kidney Int 1997;51(3):622-30
19. Kausz AT, Obrador GT, Pereira BJ. Anemia management in patients with
chronic renal insufficiency. Am J Kidney Dis 2000;36(6 Suppl 3):S39-51
20. Cohen G, Haag-Weber M, Hrl WH. Immune dysfunction in uremia. Kidney
Int 1997;52 (Suppl 62):S79-82
21. Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med
1995;333(3):166-74
22. Martinez I, Saracho R, Montenegro J, et al. The importance of dietary calcium
and phosphorus in the secondary hyperparathyroidism of patients with early renal
failure. Am J Kidney Dis 1997;29(4):496-502
23. Coburn JW, Elangovan L. Prevention of metabolic bone disease in the pre-endstage renal disease setting. J Am Soc Nephrol 1998;9(12 Suppl):S71-7
24. Fraser CL, Arieff AI. Nervous system complications in uremia. Ann Intern Med
1988;109(2):143-53
25. Obrador GT, Arora P, Kausz AT, et al. Pre-end-stage renal disease care in the
United States: a state of disrepair. J Am Soc Nephrol 1998;9(12 Suppl):S44-54
26. Pereira BJ. Optimization of pre-ESRD care: the key to improved dialysis
outcomes. Kidney Int 2000;57(1):351-65
Dr Obrador is staff physician, division of nephrology, New England Medical Center,
Boston; assistant professor of medicine, Tufts University School of Medicine, Boston;
and associate dean for academic affairs, Universidad Panamericana School of Medicine,
Mexico City. Dr Pereira is senior vice president, division of nephrology, New England
Medical Center, and professor of medicine, Tufts University School of Medicine.
Correspondence: Brian J. G. Pereira, MD, MBA, Division of Nephrology, New England
Medical Center, 750 Washington St, Box 5224, Boston, MA 02111. E-mail:
bpereira@lifespan.org.